Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN1908-1909 · 3 trials · 3 indications
Time to EAR was defined as the time to a ≥20% reduction in FEV1 or when the participant voluntarily departed the EEU due to clinically significant allergic and/or asthmatic symptoms.
The primary endpoint is the change in allergic symptom scale score at day 8
The primary endpoint is to assess treatment-emergent adverse events (TEAEs) from day 1 through day 113 (end of study).
| Arm | Type | Description |
|---|---|---|
| REGN1908-1909 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Group A | EXPERIMENTAL | Participants in group A will receive REGN1908-1909 |
| Group B | EXPERIMENTAL | Participants in group B will receive placebo |
| Cohort 1 | EXPERIMENTAL | Dose 1 of REGN1908-1909 or placebo |
| Cohort 2 | EXPERIMENTAL | Dose 2 of REGN1908-1909 or placebo |
| Cohort 3 | EXPERIMENTAL | Dose 3 of REGN1908-1909 or placebo |
| Name | Type | Description |
|---|---|---|
| REGN1908-1909 | DRUG | Single subcutaneous (SC) dose of REGN1908 and REGN1909 |
| Placebo | DRUG | Single subcutaneous (SC) dose of matching placebo |
Key Inclusion Criteria: * Documented or patient reported history (for at least 2 years) of symptomatic cat allergen-triggered asthma with rhinitis with or without conjunctivitis * No cat exposure at home for the past year and must continue having no exposure at home during the study; cat exposure o...
REGN1908-1909 is an investigational therapy being developed for cat allergy and allergy-related conditions. It is being studied in adult participants with allergies, including those with cat allergy and mild asthma. The drug is currently in clinical development and has not been approved by regulatory authorities.
REGN1908-1909 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. The company is conducting clinical trials to evaluate the safety, tolerability, efficacy, and pharmacokinetics of this investigational drug in allergic adult subjects.
REGN1908-1909 is in clinical development, with completed Phase 1 and Phase 2 trials. The Phase 1 studies evaluated safety, tolerability, efficacy, and pharmacokinetics in allergic adults, while a Phase 2 study assessed its effect on bronchoconstriction in cat-allergic patients with mild asthma. It remains investigational.
REGN1908-1909 has been studied in three completed clinical trials. NCT01922661 and NCT02127801 were Phase 1 single ascending-dose studies in allergic adults, and NCT03838731 was a Phase 2 study in cat-allergic patients with mild asthma. All trials enrolled participants aged 18 years and older.
REGN1908-1909 is a distinct investigational drug being developed by Regeneron Pharmaceuticals for cat allergy and allergy. It is not described as being the same as any other named medication. Its mechanism of action and specific characteristics are part of ongoing clinical research.